Silence Therapeutics plc (SLN) Profit Margins
Over the twelve months to 2026-06-30, Silence Therapeutics plc (SLN) had gross margin 85.9%, operating margin -11106.8%, net margin -9748.5%, free cash flow margin -6872.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SLNSilence Therapeutics plcFollow SLN — free
—
Price chart with a free account
- Market cap
- 929.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | — | 72.7% | 61.5% | 85.9% | |
| Operating margin | — | -146.4% | -16292.8% | -11106.8% | |
| Net margin | — | -104.7% | -15851.9% | -9748.5% | |
| FCF margin | — | -156.9% | -11149.6% | -6872.5% |
USD millions · SEC XBRL
Silence Therapeutics plc — questions
- What is Silence Therapeutics plc's gross margin?
- 85.9% over the twelve months to 2026-06-30.
- What is Silence Therapeutics plc's operating margin?
- -11106.8% over the twelve months to 2026-06-30.
- What is Silence Therapeutics plc's net profit margin?
- -9748.5% over the twelve months to 2026-06-30.
Every figure on this page comes from Silence Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.